Claims for Patent: 6,228,581

Summary for Patent: 6,228,581

Title:	Human intronic and polymorphic SR-BI nucleic acids and uses therefor
Abstract:	The present invention is based at least in part on the discovery of the genomic structure of the human SR-BI gene and on the identification of polymorphic regions within the gene. Accordingly, the invention provides nucleic acids having a nucleotide sequence of an allelic variant of an SR-BI gene and nucleic acids having an SR-BI intronic sequence. The invention also provides methods for identifying specific alleles of polymorphic regions of an SR-BI gene, methods for determining whether a subject has or is at risk of developing a disease which is associated with a specific allele of a polymorphic region of an SR-BI gene, and kits for performing such methods.
Inventor(s):	Acton; Susan L. (Lexington, MA), Ordovas; Jose M. (Framingham, MA)
Assignee:	Millennium Pharmaceuticals, Inc. (Cambridge, MA) Trustees of Tufts College (Boston, MA)
Application Number:	09/031,626
Patent Claims:	1. A method for determining whether a female subject has, or is at risk of developing, an abnormally high LDL level, comprising determining whether the subject has an allelic variant of a polymorphic region of an SR-BI gene that is associated with an abnormal LDL level, to thereby determine whether the subject has or is at risk of developing an abnormally high LDL level. 2. A method of claim 1, wherein the polymorphic region is located in an exon. 3. A method of claim 2, wherein the exon is exon 8. 4. A method of claim 3, wherein the polymorphic region is a nucleotide polymorphism located at nucleotide 41 of exon 8. 5. A method of claim 4, wherein the presence of a thymidine at nucleotide 41 of exon 8 of an SR-BI gene is indicative that the subject has or is likely to develop a low LDL level. 6. A method of claim 1, wherein the polymorphic region is located in an intron. 7. A method of claim 6, wherein the intron is intron 5. 8. A method of claim 7, wherein the polymorphic region is a nucleotide polymorphism located at nucleotide 54 of intron 5. 9. A method of claim 8, wherein the presence of a thymidine at nucleotide 54 of intron 5 of an SR-BI gene is indicative that the subject has or is at risk of developing an abnormally high LDL level. 10. A method for determining whether a male subject has, or is at risk of developing, an abnormally low HDL level, comprising determining whether the subject has an allelic variant of a polymorphic region of an SR-BI gene that is associated with high HDL levels, wherein the presence of an allelic variant that is associated with high HDL levels indicates that the subject has or is likely to develop a high HDL level. 11. A method of claim 10, comprising determining whether the subject comprises an adenine at nucleotide 146 in exon 1, a thymidine at nucleotide 41 in exon 8 and/or a thymidine at nucleotide 54 in intron 5, wherein the presence of an adenine at nucleotide 146 of exon 1, the presence of a thymidine at nucleotide 41 of exon 8 and/or the presence of a thymidine at nucleotide 54 of intron 5 indicates that the subject has or is a high HDL level. 12. A method of claim 1, comprising contacting a nucleic acid of the subject with at least one probe or primer which hybridizes specifically to an SR-BI gene. 13. A method of claim 12, wherein the probe or primer hybridizes specifically to a nucleic acid sequence comprising nucleotide 41 of exon 8. 14. A method of claim 13, wherein the probe or primer hybridizes specifically to a nucleic acid sequence comprising a thymidine at nucleotide 41 of exon 8. 15. A method of claim 14, wherein the probe or primer hybridizes specifically to a nucleic acid sequence of SEQ ID NO: 65 or the complement thereof. 16. A method of claim 14, wherein the probe or primer comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 67-70. 17. A method of claim 12, wherein the probe or primer hybridizes specifically to a nucleic acid sequence comprising nucleotide 54 of intron 5. 18. A method of claim 17, wherein the probe or primer hybridizes specifically to a nucleic acid sequence comprising a thymidine at nucleotide 54 of intron 5. 19. A method of claim 18, wherein the probe or primer hybridizes specifically to a nucleic acid sequence of SEQ ID NO: 66 or the complement thereof. 20. A method of claim 18, wherein the probe or primer comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 79-82. 21. A method of claim 12, wherein the probe or primer is selected from the group consisting of SEQ ID NOs: 49, 50, 55 and 56. 22. A method of claim 12, wherein the probe or primer has a nucleotide sequence from about 15 to about 30 nucleotides. 23. A method of claim 12, wherein the probe or primer is a single stranded nucleic acid. 24. A method of claim 12, wherein the probe or primer is labeled. 25. A method of claim 1, wherein determining whether the subject has an allelic variant of a polymorphic region of the SR-BI gene that is associated with an abnormal LDL level is carried out by allele specific hybridization. 26. A method of claim 1, wherein determining whether the subject has an allelic variant of a polymorphic region of the SR-BI gene that is associated with an abnormal LDL level is carried out by primer specific extension. 27. A method of claim 1, wherein determining whether the subject has an allelic variant of a polymorphic region of the SR-BI gene that is associated with an abnormal LDL level is carried out by oligonucleotide ligation assay. 28. A method of claim 1, wherein determining whether the subject has an allelic variant of a polymorphic region of the SR-BI gene that is associated with an abnormal LDL level is carried out by performing a restriction enzyme analysis. 29. A method of claim 1, wherein determining whether the subject has an allelic variant of a polymorphic region of the SR-BI gene that is associated with an abnormal LDL level is carried out by single-stranded conformation polymorphism. 30. A method of claim 10, comprising contacting a nucleic acid of the subject with at least one probe or primer which hybridizes specifically to an SR-BI gene. 31. A method of claim 30, wherein the probe or primer hybridizes specifically to a nucleic acid sequence comprising nucleotide 41 of exon 8. 32. A method of claim 31, wherein the probe or primer hybridizes specifically to a nucleic acid sequence comprising a thymidine at nucleotide 41 of exon 8. 33. A method of claim 32, wherein the probe or primer hybridizes specifically to a nucleic acid sequence of SEQ ID NO: 65 or the complement -thereof. 34. A method of claim 32, wherein the probe or primer comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 67-70. 35. A method of claim 30, wherein the probe or primer hybridizes specifically to a nucleic acid sequence comprising nucleotide 54 of intron 5. 36. A method of claim 35, wherein the probe or primer hybridizes specifically to a nucleic acid sequence comprising a thymidine at nucleotide 54 of intron 5. 37. A method of claim 36, wherein the probe or primer hybridizes specifically to a nucleic acid sequence of SEQ ID NO: 66 or the complement thereof. 38. A method of claim 36, wherein the probe or primer comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs. 79-82. 39. A method of claim 32, wherein the probe or primer hybridizes specifically to a nucleic acid sequence comprising nucleotide nucleotide 146 in exon 1. 40. A method of claim 39, wherein the probe or primes hybridizes specifically to a nucleic acid sequence comprising an adenine at nucleotide 146 in exon 1. 41. A method of claim 40, wherein the probe or primer hybridizes specifically to a nucleic acid sequence of SEQ ID NO: 95 or the complement thereof. 42. A method of claim 40, wherein the probe or primer comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 98-101. 43. A method of claim 32, wherein the probe or primer is selected from the group consisting of SEQ ID NOs: 41, 42, 49, 50, 55, and 56. 44. A method of claim 32, wherein the probe or primer has a nucleotide sequence from about 15 to about 30 nucleotides. 45. A method of claim 32, wherein the probe or primer is a single stranded nucleic acid. 46. A method of claim 32, wherein the probe or primer is labeled. 47. A method of claim 10, wherein determining whether the subject has an allelic variant of a polymorphic region of the SR-BI gene that is associated with an abnormally high HDL level is carried out by allele specific hybridization. 48. A method of claim 10, wherein determining whether the subject has an allelic variant of a polymorphic region of the SR-BI gene that is associated with an abnormally high HDL level is carried out by primer specific extension. 49. A method of claim 10, wherein determining whether the subject has an allelic variant of a polymorphic region of the SR-BI gene that is associated with an abnormally high HDL level is carried out by oligonucleotide ligation assay. 50. A method of claim 10, wherein determining whether the subject has an allelic variant of a polymorphic region of the SR-BI gene that is associated with an abnormally high HDL level is carried out by performing a restriction enzyme analysis. 51. A method of claim 10, wherein determining whether the subject has an allelic variant of a polymorphic region of the SR-BI gene that is associated with an abnormally high HDL level is carried out by single-stranded conformation polymorphism.

Details for Patent 6,228,581

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-07-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-07-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-07-10